Advanced Tissue Sciences
This article was originally published in The Gray Sheet
Executive Summary
La Jolla-based firm completes $20 mil. private placement covering the sale of 3.5 mil. shares of unregistered stock to the State of Wisconsin Investment Board. ATS filed a PMA with FDA on Aug. 25 for its Dermagraft wound dressing to treat diabetic foot ulcers (1"The Gray Sheet" Aug. 28, 2000, p. 19), three months after competitor Organogenesis received approval for its Apligraf product. Dermagraft will be marketed by Smith & Nephew
You may also be interested in...
Advanced Tissue Sciences
Firm announces submission of a premarket approval application to FDA for its Dermagraft wound dressing to treat diabetic foot ulcers. Clinical trials for the Dermagraft, which will be marketed by Smith & Nephew, indicate that the product heals significantly more ulcers than control treatment, the firm says in an Aug. 25 release. Competitor Organogenesis received an approvable recommendation from FDA's General and Plastic Surgery Devices panel in May (1"The Gray Sheet" May 15, 2000, p. 8)
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.